GIP and type 2 diabetes mellitus: Meanwhile, tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, is an emerging therapeutic option for type 2 diabetes and obesity (3).